Literature DB >> 19952787

Direct health care costs of patients with type 2 diabetes within a privately insured employed population, 2000 and 2005.

Emily D Durden1, Berhanu Alemayehu, Jonathan R Bouchard, Bong-Chul Chu, Mark Aagren.   

Abstract

OBJECTIVE: To assess the incremental economic burden of privately insured patients with type 2 diabetes (T2DM) in 2000 and 2005 in the United States.
METHODS: Adults with T2DM and 24 months of continuous health plan enrollment were identified in the MarketScan databases (2000 and 2005). Control groups of persons without diabetes were selected for comparison using propensity score matching. Total adjusted health care costs were estimated using generalized linear modeling.
RESULTS: Adjusted health care costs of patients with T2DM in 2005 were 136% higher than those of the matched controls ($12,733 vs $5406, P < 0.001). Similarly, costs of patients with T2DM in 2000 were 146% higher than those of the matched controls ($12,423 vs $5058, P < 0.001). Expenditures were similar for individuals with T2DM in 2000 and 2005.
CONCLUSIONS: T2DM continues to impose a substantial economic burden to self-insured employers.

Entities:  

Mesh:

Year:  2009        PMID: 19952787     DOI: 10.1097/JOM.0b013e3181c2bb31

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  10 in total

1.  The Effects of Diagnostic Definitions in Claims Data on Healthcare Cost Estimates: Evidence from a Large-Scale Panel Data Analysis of Diabetes Care in Japan.

Authors:  Haruhisa Fukuda; Shunya Ikeda; Takeru Shiroiwa; Takashi Fukuda
Journal:  Pharmacoeconomics       Date:  2016-10       Impact factor: 4.981

2.  Trajectory of Excess Medical Expenditures 10 Years Before and After Diabetes Diagnosis Among U.S. Adults Aged 25-64 Years, 2001-2013.

Authors:  Sundar S Shrestha; Ping Zhang; Israel A Hora; Edward W Gregg
Journal:  Diabetes Care       Date:  2018-11-19       Impact factor: 19.112

Review 3.  Impact of social determinants of health on outcomes for type 2 diabetes: a systematic review.

Authors:  Rebekah J Walker; Brittany L Smalls; Jennifer A Campbell; Joni L Strom Williams; Leonard E Egede
Journal:  Endocrine       Date:  2014-02-15       Impact factor: 3.633

4.  Medical expenditures associated with diabetes acute complications in privately insured U.S. youth.

Authors:  Sundar S Shrestha; Ping Zhang; Lawrence Barker; Giuseppina Imperatore
Journal:  Diabetes Care       Date:  2010-09-15       Impact factor: 19.112

5.  Medical expenditures associated with diabetes among privately insured U.S. youth in 2007.

Authors:  Sundar S Shrestha; Ping Zhang; Ann Albright; Giuseppina Imperatore
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112

Review 6.  The Economic Costs of Type 2 Diabetes: A Global Systematic Review.

Authors:  Till Seuring; Olga Archangelidi; Marc Suhrcke
Journal:  Pharmacoeconomics       Date:  2015-08       Impact factor: 4.981

7.  Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: a comparative retrospective database study.

Authors:  Li Wang; Wenhui Wei; Raymond Miao; Lin Xie; Onur Baser
Journal:  BMJ Open       Date:  2013-04-30       Impact factor: 2.692

8.  Improving the economic and humanistic outcomes for diabetic patients: making a case for employer-sponsored medication therapy management.

Authors:  Sharrel L Pinto; Jinender Kumar; Gautam Partha; Robert A Bechtol
Journal:  Clinicoecon Outcomes Res       Date:  2013-04-11

Review 9.  Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples.

Authors:  Lan Gao; Hao Hu; Fei-Li Zhao; Shu-Chuen Li
Journal:  PLoS One       Date:  2016-01-27       Impact factor: 3.240

10.  Medical Expenditures Associated With Diabetes Among Youth With Medicaid Coverage.

Authors:  Sundar S Shrestha; Ping Zhang; Theodore J Thompson; Edward W Gregg; Ann Albright; Giuseppina Imperatore
Journal:  Med Care       Date:  2017-07       Impact factor: 2.983

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.